Physician profile
Gary A Steinecker
NPI 1699880872
$10,007.17
in general payments reported to CMS, 2019-2025
28 companies · $22.71 in 2025
The $22.71 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,776 · 2020: $5,190 · 2021: $1,896 · 2022: $37.40 · 2023: $26.85 · 2024: $57.76 · 2025: $22.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,951.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,336.11 | 2019-2021 | |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Merck Sharp & Dohme LLC | $215.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $188.91 | 2019-2025 | |
| Athenex Pharmaceutical Division, LLC | $150.00 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Amgen INC. | $65.03 | 2020-2021 | |
| Lilly USA, LLC | $53.69 | 2019-2021 | |
| Eisai INC. | $47.80 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $38.51 | 2021 | |
| Emd Serono, INC. | $34.19 | 2020 | |
| Genentech USA, INC. | $33.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.44 | 2019 | |
| Genzyme Corporation | $31.40 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.56 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $24.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.29 | 2021 | |
| Beigene USA, INC. | $21.96 | 2021 | |
| Novo Nordisk INC | $18.15 | 2019 | |
| Abbvie INC. | $17.15 | 2019 | |
| Astellas Pharma US INC | $15.86 | 2021 | |
| Celgene Corporation | $14.78 | 2021 | |
| Janssen Biotech, INC. | $14.23 | 2021 | |
| Seagen INC. | $13.66 | 2020 | |
| Sun Pharmaceutical Industries INC. | $13.28 | 2019 | |
| Incyte Corporation | $12.79 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Steinecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.